Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
MannKind Corporation (NASDAQ: MNKD) is a biopharmaceutical company dedicated to the development and commercialization of innovative therapeutic products and devices for patients with endocrine and orphan lung diseases. Their flagship product, Afrezza® (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin approved in the United States for adults with diabetes. MannKind is also advancing a pipeline of other inhaled therapeutic candidates based on its proprietary Technosphere® inhalation technology, aiming to improve patient outcomes and convenience.
The Danbury facility serves as the main hub for MannKind's research and development, manufacturing of Afrezza® and Technosphere® particles, and corporate administrative functions.
State-of-the-art manufacturing facilities specifically designed for producing their proprietary Technosphere® dry powder formulation and the Afrezza® product. Advanced R&D laboratories.
The work culture at MannKind's headquarters emphasizes innovation, scientific rigor, collaboration, and a patient-centric approach. Employees are often engaged in cutting-edge biopharmaceutical research, development, and manufacturing processes.
This facility is crucial for MannKind as it houses the core capabilities for their Technosphere® platform, from R&D through to commercial-scale manufacturing, making it central to their business operations and future growth.
MannKind Corporation is primarily focused on the U.S. market with its lead product, Afrezza®. However, they actively pursue strategic partnerships and collaborations to expand the reach of their Technosphere® technology and pipeline products to global markets. Their global functions typically involve business development, seeking regulatory approvals in other regions through partners, and managing international collaborations for clinical development and commercialization.
1 Casper Street
Danbury
CT
USA
Address: 30930 Russell Ranch Road, Suite 300, Westlake Village, CA 91362
Serves as a key corporate site, potentially housing executive leadership, business development, marketing, and other administrative teams, benefiting from California's biopharmaceutical ecosystem.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, MannKind Corporation' leadership includes:
MannKind Corporation has been backed by several prominent investors over the years, including:
MannKind Corporation has seen some leadership adjustments, primarily at the board level, to strengthen its strategic direction and governance over the past year. The core operational executive team has remained largely consistent.
Discover the tools MannKind Corporation uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
MannKind Corporation likely utilizes common corporate email formats. The most probable format involves a combination of the employee's first initial and last name.
[first_initial][last]@mannkindcorp.com
Format
jdoe@mannkindcorp.com
Example
80%
Success rate
GlobeNewswire • March 4, 2024
MannKind Corporation announced it will present new clinical and scientific data for Afrezza® (insulin human) Inhalation Powder and its investigational product candidate, MNKD-101 (clofazimine inhalation suspension), at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Florence, Italy....more
Business Wire • February 28, 2024
MannKind Corporation reported its financial results for the fourth quarter and full year ended December 31, 2023. Highlights include record total revenues and Afrezza net revenue, driven by strong demand and commercial execution....more
GlobeNewswire • January 4, 2024
MannKind Corporation announced the appointment of Thomas C. West, M.D., J.D., M.F.A., to its Board of Directors, effective January 2, 2024. Dr. West brings over 30 years of experience in the pharmaceutical industry....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including MannKind Corporation, are just a search away.